美国国家综合癌症网络肿瘤学临床实践指南中放射治疗推荐意见的存在情况与证据等级演变
该研究对2000年、2009年和2019年三个版本NCCN指南中10种最常见肿瘤的放射治疗推荐意见及其支持证据类别进行了系统回顾与分类。共审查3858条NCCN推荐意见,包含放射治疗的推荐意见从2000年的205条增至2019年的992条(增幅383%)。2019年指南中,小细胞肺癌、非小细胞肺癌和乳腺癌的放射治疗Category 1证据比例最高,分别为29%、24%和24%。
要点
- 2000年至2019年,NCCN指南中10种最常见肿瘤的放射治疗推荐意见增幅达383%。
- 2019年指南中,放射治疗Category 1推荐最多见于小细胞肺癌(13%)、非小细胞肺癌(5%)和乳腺癌(5%)。
- 胰腺癌、子宫癌、前列腺癌、黑色素瘤、肾癌和结肠癌指南无放射治疗Category 1推荐。
核心结论
- 过去20年间,NCCN指南中10种最常见恶性肿瘤的放射治疗推荐频率增加了超过300%。
- 按肿瘤类型考量支持这些推荐意见的证据质量,有助于识别需要更高级别证据支持放射治疗作用的特定恶性肿瘤。
研究设计与样本
- 对2000年、2009年和2019年三个版本NCCN指南中10种最常见肿瘤的放射治疗推荐意见及其支持证据类别进行综合回顾与分类。
- 共个体化审查3858条NCCN推荐意见。
- 记录每种肿瘤类型指南中放射治疗作为推荐模式的存在情况,并对Category 1、2A、2B和3推荐类别进行计数和比较。
主要发现
- 包含放射治疗的推荐意见从2000年的205条增至2019年的992条(383%)。
- 2019年NCCN指南中,放射治疗Category 1推荐在小细胞肺癌为13%、非小细胞肺癌为5%、乳腺癌为5%、膀胱癌为2%、直肠癌为2%、非霍奇金淋巴瘤为1%。
- 胰腺癌、子宫癌、前列腺癌、黑色素瘤、肾癌和结肠癌指南无放射治疗Category 1推荐。
- 直肠癌有31条(27%)优选推荐。
- 2019年放射治疗推荐意见中89%为初始治疗,9%为挽救治疗专项。
关键数值与推荐
- 放射治疗Category 1证据比例最高的肿瘤部位为小细胞肺癌(29%)、非小细胞肺癌(24%)和乳腺癌(24%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The changes in the recommended use of radiation therapy (RT) in the presence of expanding systemic cancer therapies and technological advances are poorly characterized. We sought to understand the recommended utilization of RT across a broad range of malignancies by examining National Comprehensive Cancer Network (NCCN) Guidelines. METHODS AND MATERIALS: We conducted a comprehensive review and categorization of RT recommendations, with their subsequent supporting evidence categories, in 3 versions of NCCN Guidelines, specifically years 2000, 2009, and 2019. These NCCN Guidelines were individually examined for RT-specific recommendations among the 10 most common tumors. The presence of RT as a recommended modality was recorded for each tumor type in each guideline. Recommendation categories including Category 1, 2A, 2B, and 3 were tallied and compared with examine totals and percentage distributions in each tumor type. RESULTS: A total of 3858 NCCN recommendations were individually reviewed. The presence of a recommendation inclusive of RT increased from incidence of 205 in the year 2000 to 992 in the year 2019 (383%). In the 2019 NCCN Guidelines, the most Category 1 RT recommendations were found within small cell lung (13%), non-small cell lung (5%), breast (5%), bladder (2%), rectal (2%), and non-Hodgkin lymphoma (1%). Pancreatic, uterine, prostate, melanoma, kidney, and colon cancer guidelines had no Category 1 RT recommendations. Rectal cancer had 31 (27%) preferred recommendations. The majority (89%) of 2019 RT recommendations were for initial therapy, and 9% were specific to salvage therapy. Tumor sites with the highest proportion of RT Category 1 evidence were small cell lung (29%), non-small cell lung (24%), and breast cancer (24%). CONCLUSIONS: The frequency of recommendations for using RT in NCCN Guidelines has increased by >300% in the past 20 years among the 10 most common malignancies. Consideration of the quality of evidence supporting these recommendations by tumor type is useful to identify specific malignancies in need of higher-level evidence supporting the role of RT.
引用
- Conger RL, Mora J, Straza MW, et al. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Adv Radiat Oncol. 2023. PMID: 37152489. doi:10.1016/j.adro.2023.101206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。